Aims: The AMD Annals initiative, active in Italy since 2006, monitors diabetes care quality, showing continuous improvements through standardized indicators. This report presents the 2024 data on type 2 diabetes (T2D). Methods: Approximately half of the Italian diabetes centers annually extract anonymized electronic medical records data. Process, treatment and outcome indicators, and the Q-score, a validated score of overall care, were evaluated. Results: Data from 301 centers on 680,122 T2D patients (58.6 % men, mean age 69.9 years; 35.9 % > 75 years) were evaluated. HbA1c ≤ 7.0 % was achieved by 55.9 % of patients, LDL < 70 mg/dl by 44.6 %, blood pressure (BP) < 130/80 mmHg by 26.5 %, with 7.7 % meeting multiple targets. Obesity showed a prevalence of 35 %, while smoking was high (17.9 %). Pharmacological treatment improved: 72.0 % used lipid-lowering drugs, 68.8 % BP-lowering, and 97.6 % glucose-lowering drugs. As for innovative drugs, 41.9 % of patients were treated with SGLT2i and 35.5 % with GLP1 RA, with an increasing trend compared to 2023 data. Complication rates remained stable, with a further Q-score improvement. Conclusions: The 2024 data confirm ongoing improvements in T2D care, despite an aging population. Although gaps persist, the path toward aligning practice with guidelines is well established.
Russo, G.T., De Cosmo, S., Nicolucci, A., Manicardi, V., Rocca, A., Lucisano, G., et al. (2025). Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced. DIABETES RESEARCH AND CLINICAL PRACTICE, 225, 1-7 [10.1016/j.diabres.2025.112273].
Type 2 diabetes specialist care in Italy in the AMD Annals initiative 2024: The path is traced
Manicardi V.;Lucisano G.;Rossi M. C.;Di Bartolo P.;Candido R.
2025
Abstract
Aims: The AMD Annals initiative, active in Italy since 2006, monitors diabetes care quality, showing continuous improvements through standardized indicators. This report presents the 2024 data on type 2 diabetes (T2D). Methods: Approximately half of the Italian diabetes centers annually extract anonymized electronic medical records data. Process, treatment and outcome indicators, and the Q-score, a validated score of overall care, were evaluated. Results: Data from 301 centers on 680,122 T2D patients (58.6 % men, mean age 69.9 years; 35.9 % > 75 years) were evaluated. HbA1c ≤ 7.0 % was achieved by 55.9 % of patients, LDL < 70 mg/dl by 44.6 %, blood pressure (BP) < 130/80 mmHg by 26.5 %, with 7.7 % meeting multiple targets. Obesity showed a prevalence of 35 %, while smoking was high (17.9 %). Pharmacological treatment improved: 72.0 % used lipid-lowering drugs, 68.8 % BP-lowering, and 97.6 % glucose-lowering drugs. As for innovative drugs, 41.9 % of patients were treated with SGLT2i and 35.5 % with GLP1 RA, with an increasing trend compared to 2023 data. Complication rates remained stable, with a further Q-score improvement. Conclusions: The 2024 data confirm ongoing improvements in T2D care, despite an aging population. Although gaps persist, the path toward aligning practice with guidelines is well established.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
